Sanofi Draws Fire Over Cost of MS Drug Lemtrada

01.11.2012 - Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators...